New shot for hemophilia: patients share their experience
NCT ID NCT06992076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry follows 100 adults and teens with hemophilia A or B who are prescribed marstacimab, a once-weekly shot under the skin. The main goals are to see if patients prefer this shot over IV treatments and to measure treatment burden after 6 months. Researchers will also track bleeding rates and joint health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
marstacimab (a monoclonal antibody injection under the skin)
What this could lead to
If successful, this registry could show that a once-weekly shot is preferred over IV infusions and reduces bleeding episodes, improving quality of life for hemophilia patients.
What could go wrong
This is an observational registry, not a controlled trial, so results may not prove cause and effect. It is also small (100 participants) and focused on patient experience, not long-term safety or efficacy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of haematology and Blood diseases hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact
Contact
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, China
Contact